Article Information
History
- September 21, 2021.
Article Versions
- You are currently viewing Version 1 of this article (September 21, 2021 - 17:48).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Richard A. Miller1,*,
- Pramod Guru2,
- Philippe Bauer3,
- Jorge Robles4,
- Christian Tomaszewski4,5,
- J. Scott Overcash6,
- Michael Waters7,
- Miriam Cameron8,
- Julián Olalla Sierra9,
- James Janc1,
- Jenny A. Rudnick1,
- Shenshen Hu1,
- William B. Jones1,
- Long Kwei1,
- Suresh Mahabhashyam1,
- Stephen B. Willingham1 and
- Gerard Criner10
- 1Corvus Pharmaceuticals, Burlingame, CA, USA
- 2Mayo Clinic, Jacksonville, FL, USA
- 3Mayo Clinic, Rochester, MN, USA
- 4El Centro Regional Medical Center, El Centro, CA, USA
- 5University of California, San Diego, CA, USA
- 6Sharp Grossmont Hospital, La Mesa, CA, USA
- 7Sharp Chula Vista Medical Center, Chula Vista, CA, USA
- 8Holy Cross Hospital, Silver Spring, MD, USA
- 9Hospital Costa del Sol, Marbella, Spain
- 10Temple University Hospital, Philadelphia, PA, USA
- ↵*Corresponding author:
Richard Miller, Corvus Pharmaceuticals, Phone: 650-900-4521; rmiller{at}corvuspharma.com.
Posted September 21, 2021.
Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19
